Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user is experiencing worsening hair loss despite undergoing monthly injectable finasteride, clay masks, laser therapy, and microneedling. They are concerned about severe shedding in areas not typically affected by male pattern baldness and are considering seeking a second opinion.

The user reported hair recovery on the scalp after 4 months using finasteride and 5% topical minoxidil, with anxiety as a side effect. Reducing caffeine intake helped manage anxiety, which may be linked to minoxidil's effects.

Topical minoxidil can cause water retention, making the face appear swollen. Switching from liquid to foam and reducing application frequency may help; using dandelion root extract as a diuretic is also suggested.

Hair loss can be distressing, but treatments like finasteride, minoxidil, and scalp micropigmentation can help manage it. Embrace self-improvement, focus on personal goals, and maintain a positive attitude despite hair loss challenges.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

A 20-year-old with aggressive hair loss uses finasteride, dermastamping, ketoconazole shampoo, and a castor oil and rosemary oil mix. They are uncertain about continuing Ashwagandha due to mixed effects on hair loss and anxiety.

Amplifica's AMP-303 showed a modest increase in hair growth, but results were inconsistent and potentially misleading. Hyaluronic acid and osteopontin are being explored for hair growth, with varying effects on different hair types and conditions.

Microneedling can cause skin shedding and inflammation, with some users adjusting needle size or frequency to reduce these effects. Some users combine microneedling with treatments like minoxidil, while others prefer smaller needles or alternative treatments like dutasteride.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Whey protein may slightly increase hair loss in men with androgenetic alopecia (AGA) due to elevated IGF-1 and testosterone levels, but the effect is minimal compared to treatments like finasteride and dutasteride. Many users argue that whey protein's impact on hair loss is negligible and that maintaining a healthy lifestyle is more important.

Bicalutamide blocks androgen receptors, preventing testosterone and DHT from binding, which can help with hair loss but may cause feminization. It is not recommended for those who do not want feminization effects.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

The user experienced severe side effects from finasteride, including anxiety and libido issues, and is currently using topical minoxidil and microneedling. They are considering trying dutasteride but are concerned about potential side effects.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Concerns about AI-generated content accuracy and misinformation are raised.

A company is developing a topical dutasteride that targets hair follicles without significantly affecting systemic DHT levels, with trials underway to measure its effectiveness. Users discuss the potential benefits and skepticism around the formulation compared to existing treatments.

People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.

Scalp pain alongside hair loss may indicate inflammation rather than just male pattern baldness. Treatments mentioned include triamcinolone acetonide, fluocinonide, Head & Shoulders shampoo, aloe vera gel, finasteride, and 2% Nizoral.

The conversation discusses concerns about body dysmorphia related to hair loss, with some users expressing frustration over posts claiming treatments like finasteride and dutasteride are ineffective or harmful despite minimal hair loss. It emphasizes the importance of early treatment with medications like finasteride and minoxidil for those experiencing hair loss.

Many people feel self-conscious about hair loss during haircuts, with some using treatments like finasteride and minoxidil. Others cope by cutting their own hair or finding a trusted barber to manage thinning areas.

OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.

The user experienced chest pain and increased heart rate after microneedling while using topical minoxidil for hair loss. They are unsure if minoxidil is effective without microneedling.

Gym and creatine can cause hair loss by increasing testosterone and androgenic activity. DHT blockers may help some, while others need androgen suppression with topical AA like RU or Pyri.

Copper peptides GHK-Cu and AHK-Cu are discussed for hair loss treatment, with questions about their effectiveness and application methods. One user suggests sticking to traditional treatments like Minoxidil and Finasteride, as they didn't notice significant results with copper peptides.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.

Dutasteride mesotherapy for hair loss, with the user reporting minimal pain during the procedure. Other users mention success stories and inquire about additional treatments.

A 24-year-old woman with hair loss due to anemia and possibly thyroid issues is undergoing mesotherapy, which was only applied to the top of her head. She is considering minoxidil and is concerned about the effectiveness of the treatment, as her hair loss is not related to hormonal factors.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.